Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
112 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Shire Plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Shire Plc - Product Pipeline Review - 2014', provides an overview of the Shire Plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Shire Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Shire Plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Shire Plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Shire Plc's pipeline products Reasons to buy - Evaluate Shire Plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Shire Plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Shire Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Shire Plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Shire Plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Shire Plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Shire Plc Snapshot 8 Shire Plc Overview 8 Key Information 8 Key Facts 8 Shire Plc - Research and Development Overview 9 Key Therapeutic Areas 9 Shire Plc - Pipeline Review 13 Pipeline Products by Stage of Development 13 Pipeline Products - Monotherapy 14 Pipeline Products - Partnered Products 15 Partnered Products/Combination Treatment Modalities 16 Pipeline Products - Out-Licensed Products 17 Out-Licensed Products/Combination Treatment Modalities 18 Shire Plc - Pipeline Products Glance 19 Shire Plc - Late Stage Pipeline Products 19 Pre-Registration Products/Combination Treatment Modalities 19 Phase III Products/Combination Treatment Modalities 20 Shire Plc - Clinical Stage Pipeline Products 21 Phase II Products/Combination Treatment Modalities 21 Phase I Products/Combination Treatment Modalities 22 Shire Plc - Early Stage Pipeline Products 23 Preclinical Products/Combination Treatment Modalities 23 Discovery Products/Combination Treatment Modalities 24 Shire Plc - Unknown Stage Pipeline Products 25 Unknown Products/Combination Treatment Modalities 25 Shire Plc - Drug Profiles 26 anagrelide hydrochloride 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 guanfacine hydrochloride ER 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 icatibant acetate 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 velaglucerase alfa 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 C1 esterase inhibitor (human) 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 hydrocortisone MR 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 lifitegrast 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 lisdexamfetamine dimesylate 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 prucalopride succinate 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 SHP-465 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 idursulfase 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 mecasermin rinfabate 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 LUM-001 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 maribavir 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 SHP-610 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 SHP-613 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 SSP-002358 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 VP-20621 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 PVS-10200 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 SHP-611 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 LUM-002 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 SHP-622 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 HGT-3010 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 SC-435 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Small Molecule to Inhibit A2A Receptor for CNS Disorders 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Antisense Oligonucleotide For Rare Genetic Disorders 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 etiguanfacine 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Shire Plc - Pipeline Analysis 69 Shire Plc - Pipeline Products by Target 69 Shire Plc - Pipeline Products by Route of Administration 71 Shire Plc - Pipeline Products by Molecule Type 72 Shire Plc - Pipeline Products by Mechanism of Action 73 Shire Plc - Recent Pipeline Updates 75 Shire Plc - Dormant Projects 96 Shire Plc - Discontinued Pipeline Products 99 Discontinued Pipeline Product Profiles 99 NRP-290 99 SPD-452 99 SPD-453 100 SPD-756 100 anagrelide hydrochloride 100 CX-516 100 HCV-796 100 HGT-1111 100 HGT-2610 100 lisdexamfetamine dimesylate 100 mesalamine ER 101 metoclopramide hydrochloride 101 ramatercept 101 SHP-557 101 SPD-427 101 SPD-491 101 SPD-554 101 SPD-556 102 valrocemide 102 Shire Plc - Company Statement 103 Shire Plc - Locations And Subsidiaries 104 Head Office 104 Other Locations & Subsidiaries 104 Shire Plc - Key Manufacturing Facilities 110 Appendix 111 Methodology 111 Coverage 111 Secondary Research 111 Primary Research 111 Expert Panel Validation 111 Contact Us 112 Disclaimer 112
List of Tables Shire Plc, Key Information 8 Shire Plc, Key Facts 8 Shire Plc - Pipeline by Indication, 2014 11 Shire Plc - Pipeline by Stage of Development, 2014 13 Shire Plc - Monotherapy Products in Pipeline, 2014 14 Shire Plc - Partnered Products in Pipeline, 2014 15 Shire Plc - Partnered Products/ Combination Treatment Modalities, 2014 16 Shire Plc - Out-Licensed Products in Pipeline, 2014 17 Shire Plc - Out-Licensed Products/ Combination Treatment Modalities, 2014 18 Shire Plc - Pre-Registration, 2014 19 Shire Plc - Phase III, 2014 20 Shire Plc - Phase II, 2014 21 Shire Plc - Phase I, 2014 22 Shire Plc - Preclinical, 2014 23 Shire Plc - Discovery, 2014 24 Shire Plc - Unknown, 2014 25 Shire Plc - Pipeline by Target, 2014 70 Shire Plc - Pipeline by Route of Administration, 2014 71 Shire Plc - Pipeline by Molecule Type, 2014 72 Shire Plc - Pipeline Products by Mechanism of Action, 2014 74 Shire Plc - Recent Pipeline Updates, 2014 75 Shire Plc - Dormant Developmental Projects,2014 96 Shire Plc - Discontinued Pipeline Products, 2014 99 Shire Plc, Other Locations 104 Shire Plc, Subsidiaries 105 Shire Plc, Key Manufacturing Facilities 110
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
